Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eExos-miR-124
- Development stage
- Preclinical
- Lead developer
- Baylor College of Medicine
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
eExos-miR-124 is an engineered exosome-based gene delivery tool designed for the treatment of glioblastoma. These exosomes (eExos) are modified to express retroviral Gag and VSVg proteins, which enhances the packaging efficiency of genetic cargo and facilitates cellular entry. The therapeutic payload is microRNA-124 (miR-124), a potent anti-glioma microRNA identified through high-throughput screening for its ability to inhibit the proliferation of glioma stem cells (GSCs). In preclinical models, eExos-miR-124 has demonstrated the ability to deliver miR-124 to brain tumor cells, leading to decreased tumor cell proliferation and improved survival in mouse models of glioma. The platform aims to overcome delivery barriers in the central nervous system by utilizing the natural trafficking properties of exosomes combined with viral protein-mediated enhancement.
- Other names
- engineered exosomes expressing miR-124
Beyond the preview
Go deeper on eExos-miR-124.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eExos-miR-124.